Co-Authors
This is a "connection" page, showing publications co-authored by Thomas Hanff and James Byrd.
Connection Strength
0.169
-
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021 03; 9(3):275-284.
Score: 0.058
-
Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich). 2020 10; 22(10):1780-1788.
Score: 0.056
-
Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". Circ Res. 2020 06 05; 126(12):e140-e141.
Score: 0.055